Bonifati and Graceffa reported 7 patients who experienced worsening or a flare of psoriatic arthritis after they were switched from TNF-α inhibitors to ustekinumab, suggesting that ustekinumab has better performance on skin symptoms than on joint inflammation [122]. This evidence concerns the gene TNF and psoriatic arthritis.